Boy with Bike)

Our Patients

Our Promise to Patients: You Come First

Welcome home

You've likely had a long journey, but now you're among friends. We understand rare and serious conditions because we've specialized in it for decades and we're here to help. By working closely with people like Omar (pictured above), we're able to identify and pursue new innovations that address unmet medical needs. Meanwhile, we continue to enhance our current treatments for conditions, including immunodeficiency and autoimmune diseases, hereditary and acquired bleeding disorders, hereditary angioedema, and Alpha-1 antitrypsin deficiency.   

We are driven by our promise to save lives and improve the quality of life for our patients and their families, because living with a rare disease impacts more than just one person. We offer support programs and activities and we partner with patient advocacy organizations to improve and expand educational and outreach efforts. We also work with government authorities to ensure patients have access to the medicines they need to live life to the fullest.

How can we help you?

Immunodefiency & Autoimmune Diseases

We offer one of the most comprehensive portfolios of high-quality, technically advanced immunoglobulin (Ig) therapies and we are the leading Ig manufacturer in the world. Treatments are available for the following conditions:

Within the United States:
- Primary Immunodeficiency
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Idiopathic Thrombocytopenic Purpura (ITP)

Outside the United States:
- Primary Immunodeficiency
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Idiopathic Thrombocytopenic Purpura (ITP)
- Secondary Immunodeficiency
- Multifocal Motor Neuropathy (MMN)
- Guillain-Barré Syndrome (GBS)

Hereditary Bleeding Disorders

We are a world leader in innovative medicines for the treatment of bleeding disorders. We offer the largest portfolio for the treatment of hereditary bleeding disorders with more than a dozen plasma-derived and recombinant coagulation factor concentrates. Treatments are available for the following conditions:

Within the United States:
- Hemophilia A
- Hemophilia B
- von Willebrand Disease
- Factor XIII Deficiency
- Fibrinogen Deficiency

Outside the United States:
- Factor X Deficiency

Hereditary Angioedema (HAE)

We recently introduced the world's first subcutaneous preventative treatment for attacks of Hereditary Angioedema (HAE), while still offering our intravenous C1-esterase inhibitor therapy for on-demand treatment.

Alpha-1 Antitrypsin Deficiency

Our alpha-1 proteinase inhibitor treats Alpha-1 Antitrypsin Deficiency (AATD) in patients with alpha-1-related emphysema.

Mother on beach with teenage daughter Mother on beach with teenage daughter

Life has changed for the better now. She's full of life and energy.

- Annette Gregory, Mother of Primary Immunodeficiency Patient Baylee

Current Clinical Trials

Therapeutic Area Condition Description
Bleeding Disorders
Hemophilia A An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A. Learn More
Congenital Fibrinogen Deficiency An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency Learn More
Von Willebrand Study of Voncento® in Subjects With Von Willebrand Disease Learn More
Hemophilia B
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B Learn More
Immune Deficiencies Primary Immune Deficiency (PID) Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) Learn More
Primary Immune Deficiency (PID) Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Learn More
Therapeutic Proteins Other Inflammatory or immune system disorders Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Learn More
Antibody-mediated kidney transplant rejection Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Learn More

Participate in a Clinical Trial

Discover what is involved in participating in one of our clinical trials and how you can enroll.

Learn More

Get our latest news in your inbox

mail@example.com
First name
Last name
Country

Thanks!

You have now been added
to the CSL Behring news list